Comparing Neo-Putty Bioactive Bioceramic MTA to Formocresol for Vital Pulpotomy in Primary Molars of Children Aged 4 to 9 Years A Randomized Clinical Trial

What this Trial Is About

Researchers are evaluating the clinical and radiographic effects of a new premixed Bioactive bioceramic MTA called Neo-Putty compared to Formocresol in vital pulpotomy treatments of primary molars in children aged 4 to 9 years. This randomized clinical trial aims to determine if Neo-Putty offers better clinical success and fewer adverse effects, addressing concerns about toxic reactions and tissue damage associated with Formocresol. The trial involves two groups one receiving Formocresol applied with a cotton pellet on the amputated pulp for 5 minutes followed by coverage with an intermediate restorative material IRM, and the other treated with Neo-Putty placed directly on the pulp stumps after coronal pulp removal and hemostasis, then covered with reinforced Zinc Oxide-Eugenol IRM. Treatments are given in a single procedure, with the trial designed as a randomized, parallel group, single-blinded study. Participants will be monitored over 12 months with clinical and radiographic evaluations at 3, 6, 9, and 12 months to assess treatment success, including symptom-free status and absence of pulp degeneration signs such as pain, bleeding, root resorption, and bone destruction. The study involves regular follow-up visits to observe healing and detect any complications, supporting improved pediatric dental care practices.

Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol